Fig. S2 Progression-free survival of the patients who received BD regimen (A) or TD regimen (B) based on the presence or absence of *FGFR3* or *c-MAF* mRNA expression which is the hallmark of high-risk group

A. BD therapy arm




Fig. S2 Progression-free survival of the patients who received BD regimen (A) or TD regimen (B) based on the presence or absence of *FGFR3* or *c-MAF* mRNA expression which is the hallmark of high-risk group

B. TD therapy arm

